– Xtampza ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million …

Wertpapier:

– Strengthened Formulary Access for Xtampza ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations – – Adjusted EBITDA of $41.8 Million – – Conference Call Scheduled …

Wertpapier:
Diskussionen

Collegium Pharmaceutical Forum

Die wichtigsten Links der Community
Forum-Suche

Diskussionen

Was halten Sie von den neusten Entwicklungen zu Collegium Pharmaceutical?


Meistdiskutierte Aktien (24h)

WertpapierBeiträge
250
228
144
132
120
109
106
99
95
80